Peptech gets green light for dog contraceptive
23 September, 2003 by Graeme O'NeillSydney peptide and protein therapeutics developer Peptech Ltd (ASX:PTD ) has announced that its fully owned subsidiary, Peptech Animal Health (PAH) has received approval to market its Suprelorin six-month contraceptive for dogs in Australia.
ATP Innovations signs MoU with CSU, Wagga Wagga
23 September, 2003 by Tanya HollisTechnology business commercialisation centre ATP Innovations has entered an agreement with Charles Sturt University and Wagga Wagga City Council to help put research on the track to market.
Acrux in major deal with Eli Lilly
23 September, 2003 by Tanya HollisMelbourne drug delivery systems developer Acrux has signed a major deal with global pharmaceutical group Eli Lilly and Company to commercialise its veterinary product line.
New study to explore genetics of eczema
22 September, 2003 by Tanya HollisA tri-state research collaboration is set to use sibling pairs to examine the genetic reasoning behind the most common form of eczema
CSIRO livestock researchers explore potential of new technologies
22 September, 2003 by Graeme O'NeillTwo animal-virus hunters at CSIRO are exploring the potential of advanced genetic and proteomics technologies to make more accurate and rapid diagnoses of viral diseases and other microbial infections of livestock.
Virax raises $3.4m
22 September, 2003 by Tanya HollisDevelopment-stage biotechnology company Virax Holdings (ASX: VHL) has raised $3.4 million in a capital raising aimed to progress its prostate cancer and HIV drug development programs.
New CEO at Peplin Biotech
22 September, 2003 by Tanya HollisBrisbane small molecule drug development company Peplin Biotech (ASX: PEP) today announced the appointment of its new chief executive.
Hunter research labs team with Amersham in new project
19 September, 2003 by Graeme O'NeillThe University of Newcastle and the Hunter Medical Research Institute have linked up with international life sciences supply company Amersham BioSciences to establish a sophisticated analytical laboratory for research into personalised medicine.
Cardia spin-off slated for funds, IPO
19 September, 2003 by Tanya HollisResearch into a promising new anti-diabetes compound derived from tree bark will receive a major funding boost under a heads of agreement deal brokered in Melbourne this week.
Progen raises $9.6m in share placement
19 September, 2003 by Tanya HollisSmall molecule drug company Progen Industries (ASX:PGL, Nasdaq:PGLAF) has doubled its cash reserves in a share placement aimed to help the Brisbane biotech expand its product pipeline.
Starpharma teams with IDT, AGT to test and develop drugs
18 September, 2003 by Tanya HollisIt has been a week for collaborations at the Melbourne-based polyvalent nanotechnology development company, Starpharma (ASX:SPL).
TGR boss joins Novogen board
17 September, 2003 by Tanya HollisBioactive compound development company Novogen (ASX:NRT) has appointed the chief of biotech TGR BioSsciences to its board of directors.
Vic govt tenders for review of biotech plan
17 September, 2003 by Melissa TrudingerThe Victorian state government's Department of Innovation, Industry and Regional Development (DIIRD) has put up for tender the review of its Biotechnology Strategic Development Plan.
Broaden your audience, analyst tells biotechs
16 September, 2003 by Melissa TrudingerBiotechnology companies need to widen the audiences they pitch their messages to, industry analyst David Blake, of BioShares, told attendees at a BioMelbourne Network breakfast meeting today.
Eiffel nets $2.2m Start grant
16 September, 2003 by Graeme O'NeillMelbourne drug re-engineering company Eiffel Technologies Ltd (ASX:EIF) has received a pleasant surprise from the Federal Government: a $2.2 million R&D Start grant.
